Herter, Sylvia
F. Hoffmann-La Roche AG
3 papers on CoChatORCID 0000-0002-2446-696X
Most cited papers
- Verified
Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions
Schlothauer, T., Herter, S., Koller, C. F., Grau-Richards, S., Steinhart, V., Spick, C., Kubbies, M., Klein, C., Umaña, P., & Mössner, E. (2016) · Protein Engineering Design and Selection
Monoclonal and Polyclonal Antibodies ResearchProtein purification and stability
Cited by 425
- Verified
Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
Herter, S., Herting, F., Mundigl, O., Waldhauer, I., Weinzierl, T., Fauti, T., Muth, G., Ziegler-Landesberger, D., Van Puijenbroek, E., Lang, S., et al. (2013) · Molecular Cancer Therapeutics
Lymphoma Diagnosis and TreatmentMonoclonal and Polyclonal Antibodies Research
Cited by 366
- Verified
Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Leclercq-Cohen, G., Steinhoff, N., Albertí Servera, L., Nassiri, S., Danilin, S., Piccione, E., Yángüez, E., Hüsser, T., Herter, S., Schmeing, S., et al. (2023) · Clinical Cancer Research
CAR-T cell therapy researchMonoclonal and Polyclonal Antibodies Research
Cited by 65
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free